As research continues to point to a connection between the immune system and schizophrenia, a study of innate immunity in patients with first episode psychosis and schizophrenia provides further insights into the potential mechanisms of this link.
Brian Miller, MD, PhD, MPH
TMS for TRS? Researchers analyzed data to identify all randomized-controlled trials of rTMS versus sham treatment in patients with hard-to-treat forms of schizophrenia. Here’s what they found.
Negative symptoms, subsyndromal depressive symptoms, and functional impairment often persist in patients with first-episode schizophrenia.
Protein insolubility has been found to occur in a subset of patients with schizophrenia.
Memory impairments have been shown to compromise quality of life in patients with schizophrenia. Findings from a recent study show that insulin resistance may be an underlying cause of memory loss in this population.
Current trials are investigating adjunctive monoclonal antibody immunotherapy in schizophrenia. Take the quiz and learn more.
Changes in social behavior on a mobile device may indicate relapse risk that could be assessed in the clinical setting.
Promising results from a phase 2 trial of olanzapine plus samidorphan in patients with schizophrenia.
5 questions to test your skills, based on recent findings in the literature.
In this quiz, learn which medical disorders patients with schizophrenia and comorbid TD are likely to contend with.